

# Karin Jordan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2097824/publications.pdf>

Version: 2024-02-01

16  
papers

1,434  
citations

1040018

9  
h-index

1058452

14  
g-index

16  
all docs

16  
docs citations

16  
times ranked

2035  
citing authors

#	ARTICLE	IF	CITATIONS
1	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 2017, 35, 3240-3261.	1.6	454
2	Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncology, The, 2018, 19, e588-e653.	10.7	452
3	Antiemetics: American Society of Clinical Oncology Focused Guideline Update. Journal of Clinical Oncology, 2016, 34, 381-386.	1.6	173
4	International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): Content and implementation in daily routine practice. European Journal of Pharmacology, 2014, 722, 197-202.	3.5	151
5	Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicityâ€”state of the art. Supportive Care in Cancer, 2011, 19, 43-47.	2.2	87
6	Supportive Treatments for Patients with Cancer. Deutsches A&#x0308;rztblatt International, 2017, 114, 481-487.	0.9	32
7	Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?â€”a systematic review and meta-analysis. Supportive Care in Cancer, 2018, 26, 21-32.	2.2	22
8	Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data. Oncologist, 2021, 26, e1073-e1082.	3.7	20
9	Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple Myeloma. Cancers, 2021, 13, 4706.	3.7	11
10	How I treat cancer: treatment of rheumatological side effects of immunotherapy. ESMO Open, 2020, 4, e000529.	4.5	9
11	Local Radiation Therapy Before and During Induction Delays Stem Cell Mobilization and Collection in Multiple Myeloma Patients. Transplantation and Cellular Therapy, 2021, 27, 876.e1-876.e11.	1.2	8
12	Is PFS the Right Endpoint to Assess Outcome of Maintenance Studies in Multiple Myeloma? Results of a Patient Survey Highlight Quality-of-Life As an Equally Important Outcome Measure. Blood, 2021, 138, 836-836.	1.4	6
13	Validation of a proxyâ€”reported SARCâ€”F questionnaire for current and retrospective screening of sarcopeniaâ€”related functional impairments. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 264-275.	7.3	6
14	Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice. Current Cancer Drug Targets, 2022, 22, 806-824.	1.6	2
15	Supplemental parenteral nutrition: decisions based on weak evidence. ESMO Open, 2020, 5, e000831.	4.5	1
16	Impact of Novel Therapies on CD4-T-Cell-Numbers and Infectious Complications in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2020, 136, 14-14.	1.4	0